Canada markets closed

Adamis Pharmaceuticals Corporation (ADMP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.4748+0.0049 (+1.04%)
At close: 04:00PM EDT
0.4800 +0.01 (+1.10%)
After hours: 04:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.4699
Bid0.4701 x 2200
Ask0.4789 x 2900
Day's Range0.4500 - 0.4900
52 Week Range0.3100 - 1.4800
Avg. Volume719,816
Market Cap71.093M
Beta (5Y Monthly)1.27
PE Ratio (TTM)N/A
EPS (TTM)-0.2730
Earnings DateAug 15, 2022 - Aug 19, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.42
  • GlobeNewswire

    Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19

    DSMB Has Reviewed Interim Clinical and Safety Data and Recommended that the Study ContinueSAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, today announced that a meeting of the Data Safety Monitoring Board (DSMB) overseeing the Company’s Phase 2/3 clinical trial investigating the use of Tempol for the tre

  • Zacks

    What Makes Adamis (ADMP) a New Buy Stock

    Adamis (ADMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  • GlobeNewswire

    Adamis Appoints Vickie Reed to Board of Directors

    New Director Named with Significant Executive Management and Financial Leadership ExperienceSAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Vickie Reed as a new director and member of the company’s board of directors. Richard Williams, Chairman of the Board, commented: “We are pleased to welcome Ms. Reed to the Board and look forward to working with her to pursue long-term stockholder value. Her substantial expertis